ACPE Activity Number: 0204-0000-21-415-H01-P
Activity Date: July 21, 2021
Expiration Date: July 21, 2022
Activity Type: Application-based
CE Credits: 1.0 hour
Activity Fee: Free of charge
The worldwide COVID-19 pandemic has strained health systems like never before. Since the pandemic shut the world down in March 2020, much has been learned about how to manage the disease and improve patient outcomes. This educational activity will review existing clinical data on the use of antiviral therapies, anti-inflammatory management, as well as supportive care in patients with COVID-19. Guideline recommendations on these treatments in hospitalized patients with COVID-19 will also be explained. The activity will include several clinical cases that illustrate the pharmacist’s role in the management of patients with COVID-19.
More in this Series
Expert Insight: Immunomodulators for Patients with COVID-19
Expert Insight: Antivirals for Patients with COVID-19: Now and the Future
Engaging the Experts: COVID-19 Chat with the Experts: Remdesivir and Supportive Care in Patients with COVID-19
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity was planned to meet the educational needs of pharmacists who practice in hospitals and treat patients with COVID-19.
At the conclusion of this activity, participants should be able to:
- Differentiate between guideline recommendations for the use of remdesivir in the treatment of COVID-19.
- Summarize evidence for the use of pharmacologic and supporting therapies in the treatment of COVID-19.
- Using a clinical case study, recommend a treatment plan for a patient hospitalized with COVID-19.
Paul M. Szumita, Pharm.D., BCPS, BCCCP, FASHP, FCCM, Activity Chair
Director, Clinical Pharmacy Services
Program Director-PGY2 Critical Care Pharmacy Practice Residency
Brigham and Women’s Hospital
Paul M. Szumita, Pharm.D., BCPS, BCCCP, FASHP, FCCM, is Director of Clinical Pharmacy Services and Program Director of the PGY-2 Critical Care pharmacy residency at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Szumita is a fellow in the American College of Critical Care Medicine and ASHP. Dr. Szumita is responsible for directing clinical programs aimed at optimizing pharmacotherapy and improving patient outcomes. He has more than 70 peer-reviewed publications and serves on several committees focused on improving clinical practice at the local, regional, and national level, including the program advisory board for the ASHP Critical Care Pharmacy Specialty Board Examination Review Course.
Jeffrey C. Pearson, Pharm.D., BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
Brigham and Women’s Hospital
Jeffrey C. Pearson, Pharm.D., BCIDP, is Clinical Pharmacy Specialist in Infectious Diseases at Brigham and Women’s Hospital in Boston, Massachusetts, where he serves as the point person for the hospital’s antimicrobial stewardship program and COVID-19 therapeutic guidelines. Dr. Pearson received his Doctor of Pharmacy degree from Northeastern University in 2014. He completed his PGY-1 residency at Mount Auburn Hospital in Cambridge, Massachusetts and PGY-2 residency in Infectious Diseases at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He can be reached on Twitter at @jeffpears0n.
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their relevant financial relationships.
No persons associated with this activity have disclosed any relevant financial relationships.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View the entire presentation and answer all polling questions.
- Click "Complete Activity" on last slide to complete assessment and evaluation and claim credit.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
Provided by ASHP
Supported by an educational grant from Gilead